News

Diagnosis of T-cell and natural killer (NK) cell neoplasias can be a challenge! These diseases are relatively rare and often show complex and heterogeneous immunophenotypes that may closely resemble reactive or activated lymphocyte populations. As a result, distinguishing between benign immune responses and true malignant proliferation requires careful interpretation of laboratory findings.
From June 1 to 5, 2026, EuroFlow will organize the 1st EuroFlow Course on immunophenotypic profiling of T/NK-cell neoplasms. In this course, we will explore the key principles of flow cytometric diagnosis and classification of T-cell and NK-cell neoplasms. EuroFlow experts will give deep insights into T- and NK-cell ontogeny and differentiation, and discuss pathologies of the immature and mature cell compartments. Diagnosis, clonality assessment and classification, as well as monitoring by flow-cytometry will be demonstrated in a case-based approach. The registration is open.

Last week, the EuroFlow consortium welcomed 40 professionals from six continents to Prague for the 2nd EuroFlow Winter Course on MRD.
During this intensive three-day program, which was held in the beautiful Karolinum complex of the Charles University, experts shared insights on B- and T-lymphoblastic leukemia (B-ALL, T-ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).

The organization of the EuroFlow EQA schemes has formally been adopted by ESLHO. All EQA programs of the ESLHO consortia, EuroClonality, EuroFlow, and EuroMRD, have made this transition.

The first week of November we experienced an inspiring ESLHO Week — bringing together the three consortia EuroFlow, EuroClonality, and EuroMRD, along with several subgroups within and across them, in Brno, Czech Republic.

ESLHO, together with the three consortia EuroFlow, EuroClonality, and EuroMRD, is pleased to announce the next OPEN 15th ESLHO Symposium on “MRD monitoring and beyond.”